MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

Clinical Trials

5.0k

Active:1712
Completed:2477

Trial Phases

6 Phases

Early Phase 1:2
Phase 1:2253
Phase 2:662
+3 more phases

Drug Approvals

69

SFDA:52
NMPA:17

Drug Approvals

Elranatamab Injection

Product Name
易瑞欧
Approval Number
国药准字SJ20250011
Approval Date
Mar 4, 2025
NMPA

Elranatamab Injection

Product Name
易瑞欧
Approval Number
国药准字SJ20250010
Approval Date
Mar 4, 2025
NMPA

Rimegepant Sulfate Orally Disintegrating Tablets

Product Name
乐泰可
Approval Number
国药准字HJ20240004
Approval Date
Jan 23, 2024
NMPA

Ritlecitinib Tosylate Capsules

Product Name
乐复诺
Approval Number
国药准字HJ20230118
Approval Date
Oct 18, 2023
NMPA

Azithromycin for injection

Product Name
希舒美
Approval Number
国药准字HJ20130831
Approval Date
Sep 22, 2023
NMPA

Azithromycin for Injection

Product Name
希舒美
Approval Number
国药准字HJ20130830
Approval Date
Sep 22, 2023
NMPA

Azithromycin for Injection

Product Name
希舒美
Approval Number
国药准字HJ20140685
Approval Date
Sep 22, 2023
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220031
Approval Date
Apr 8, 2022
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220029
Approval Date
Apr 8, 2022
NMPA

Abrocitinib Tablets

Product Name
希必可
Approval Number
国药准字HJ20220030
Approval Date
Apr 8, 2022
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (3902 trials with phase data)• Click on a phase to view related trials

Phase 1
2253 (57.7%)
Phase 3
674 (17.3%)
Phase 2
662 (17.0%)
Phase 4
233 (6.0%)
Not Applicable
74 (1.9%)
phase_1_2
3 (0.1%)
Early Phase 1
2 (0.1%)
phase_2_3
1 (0.0%)

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

Completed
Conditions
COVID-19
Interventions
Drug: nirmatrelvir-ritonavir
First Posted Date
2025-07-29
Last Posted Date
2025-07-29
Lead Sponsor
Pfizer
Target Recruit Count
14000
Registration Number
NCT07090486
Locations
🇺🇸

Pfizer New York, New York, New York, United States

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Not Applicable
Not yet recruiting
Conditions
Advanced/Metastatic Solid Tumors
Bladder Cancer
Urothelial Carcinoma
Advanced Non-Small Cell Lung Cancer
Carcinoma, Non Small Cell Lung
Carcinoma, Squamous Cell of Head and Neck
Head and Neck Cancer
Esophageal Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Squamous Cell Carcinoma
Interventions
Drug: PF-08046876
First Posted Date
2025-07-29
Last Posted Date
2025-07-29
Lead Sponsor
Pfizer
Target Recruit Count
310
Registration Number
NCT07090499

A Study to Learn About the Study Medicine Paxlovid (Nirmatrelvir + Ritonavir) in Adults Aged 60 and Older Living in Korean Long-term Care Hospitals Who Have COVID-19

Not yet recruiting
Conditions
Coronavirus Disease 2019 (COVID-19)
Interventions
First Posted Date
2025-07-28
Last Posted Date
2025-07-28
Lead Sponsor
Pfizer
Target Recruit Count
1200
Registration Number
NCT07089680

A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

Not Applicable
Not yet recruiting
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Pfizer
Target Recruit Count
60
Registration Number
NCT07086664
Locations
🇺🇸

Javara - Nevada Health Centers - Carson City, Carson City, Nevada, United States

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

Not yet recruiting
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Cancer of the Prostate
Prostate Neoplasms
Prostate Cancer
Interventions
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Pfizer
Target Recruit Count
1300
Registration Number
NCT07086651
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 637
  • Next

News

Basilea Launches Phase 3 Trial for Novel Antifungal Fosmanogepix in Invasive Mold Infections

Basilea Pharmaceutica has initiated FORWARD-IM, a phase 3 registrational study evaluating fosmanogepix for treating invasive mold infections in adults, with completion expected in Q1 2028.

Ivonescimab Demonstrates Superior Efficacy in Phase III Lung Cancer Trials, Positioning for Global Regulatory Approvals

Ivonescimab, a PD-1/VEGF bispecific antibody, achieved a 48% reduction in progression-free survival risk compared to chemotherapy in EGFR-mutated NSCLC patients.

Comprehensive Pipeline Analysis Reveals 200+ Investigational Drugs for Metastatic Hormone Refractory Prostate Cancer

A new comprehensive report analyzes over 200 pipeline drugs from 180+ companies targeting metastatic hormone refractory prostate cancer, highlighting the extensive research efforts in this challenging therapeutic area.

Bristol Myers Squibb Appoints AstraZeneca's Cristian Massacesi as New Chief Medical Officer

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.

EU Regulatory Approval Advances Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for 2025-2026 Season

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.

Roche Explores Direct-to-Consumer Drug Sales Model to Reduce US Patient Costs

Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.

RedHill Biopharma Receives FDA Approval for Groundbreaking MAP-Targeted Crohn's Disease Study

RedHill Biopharma received positive FDA feedback for the first-ever clinical study targeting Mycobacterium avium subspecies paratuberculosis (MAP) infected Crohn's disease patients with RHB-204.

Turkish Study Links Pfizer COVID-19 Vaccine to Corneal Structural Changes

A Turkish study of 64 patients found measurable corneal changes 75 days after receiving two doses of the Pfizer-BioNTech COVID-19 vaccine, including 2% increased thickness and 8% reduced endothelial cell density.

BioNTech Chief Strategy Officer Ryan Richardson to Step Down After Seven-Year Tenure

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

Bristol Myers Squibb and Pfizer Launch Direct-to-Patient Eliquis Program with 40% Price Discount

Bristol Myers Squibb and Pfizer announced a new direct-to-patient purchasing option for Eliquis (apixaban) through their Eliquis 360 Support program, offering eligible patients a cash price more than 40% below the current $606 list price.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.